argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis

Thursday, January 5, 2017 1 min read

Key Takeaway: argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis

Full Press Release Details

argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis.